Picture EBD Group Biotech Showcase 2024 San Francisco 650x100px

Document › Details

MorphoSys AG. (5/3/23). "Press Release: MorphoSys AG Reports First Quarter 2023 Financial Results". Planegg.

	Organisation	MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
	Group	MorphoSys (Group)
	Organisation 2	Incyte Corporation (Nasdaq: INCY)
	Group	Incyte Corporation (Group)
	Product	Minjuvi® / Monjuvi®
	Product 2	pelabresib (CPI-0610)
	Person	Kress, Jean-Paul (MorphoSys 201909– CEO before Syntimmune + Biogen + Sanofi Genzyme)
	Person 2	Crabtree, Lucinda (MorphoSys 202307c– CFO before Autolus + Woodford Investment + Panmure Gordon + Goldman Sachs)

Original document
accessed by [iito] on 2023-05-05

Record changed: 2023-10-21

Picture Berlin Partner Voices from HealthCapital Charpentier 650x200px

More documents for MorphoSys (Group)

[1] MorphoSys AG. (3/14/23). "Press Release: Lucinda Crabtree to Join MorphoSys as Chief Financial Officer". Planegg....
[2] MorphoSys AG. (3/2/23). "Press Release: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs". Planegg....
[3] MorphoSys AG. (12/20/22). "Press Release: Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023". Planegg....
[4] MorphoSys AG. (12/6/22). "Press Release: MorphoSys Out Licenses Pre-Clinical Oncology Program". Planegg....
[5] MorphoSys AG. (11/14/22). "Press Release: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease". Planegg....
[6] Roche. (11/14/22). "Press Release: Roche Provides Update on Phase III GRADUATE Programme Evaluating Gantenerumab in Early Alzheimer’s Disease". Basel....
[7] MorphoSys AG. (10/27/22). "Press Release: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis". Planegg....
[8] MorphoSys AG. (8/31/22). "Press Release: MorphoSys Appoints Tim Demuth as New Chief Research and Development Officer, Following the Retirement of Malte Peters". Planegg....
[9] MorphoSys AG. (6/14/22). "Press Release: MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210". Planegg & South San Francisco, CA....
[10] MorphoSys AG. (3/10/22). "Press Release (Ad hoc): MorphoSys AG Reports Non-cash Impairment Charge of approx. € 231 Million on Goodwill after Consolidation of Research and Discovery Functions, Corresponding Increase of Group Operating Expenses in 2021". P...

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]